BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 11502801)

  • 21. Antihyperglycemic effects of stevioside in type 2 diabetic subjects.
    Gregersen S; Jeppesen PB; Holst JJ; Hermansen K
    Metabolism; 2004 Jan; 53(1):73-6. PubMed ID: 14681845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucose-dependent insulinotropic polypeptide and insulin-like immunoreactivity in saliva following sham-fed and swallowed meals.
    Messenger B; Clifford MN; Morgan LM
    J Endocrinol; 2003 Jun; 177(3):407-12. PubMed ID: 12773121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
    Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ethanol with a mixed meal decreases the incretin levels early postprandially and increases postprandial lipemia in type 2 diabetic patients.
    Dalgaard M; Thomsen C; Rasmussen BM; Holst JJ; Hermansen K
    Metabolism; 2004 Jan; 53(1):77-83. PubMed ID: 14681846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy.
    Fukase N; Manaka H; Sugiyama K; Takahashi H; Igarashi M; Daimon M; Yamatani K; Tominaga M; Sasaki H
    Acta Diabetol; 1995 Oct; 32(3):165-9. PubMed ID: 8590785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes.
    Thomsen C; Storm H; Holst JJ; Hermansen K
    Am J Clin Nutr; 2003 Mar; 77(3):605-11. PubMed ID: 12600850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients.
    Fukase N; Igarashi M; Takahashi H; Manaka H; Yamatani K; Daimon M; Tominaga M; Sasaki H
    Diabet Med; 1993; 10(1):44-9. PubMed ID: 8435987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.
    Meier JJ; Nauck MA; Kranz D; Holst JJ; Deacon CF; Gaeckler D; Schmidt WE; Gallwitz B
    Diabetes; 2004 Mar; 53(3):654-62. PubMed ID: 14988249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects.
    Hansen KB; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1363-70. PubMed ID: 22319034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
    Meier JJ; Kemmeries G; Holst JJ; Nauck MA
    Diabetes; 2005 Jul; 54(7):2212-8. PubMed ID: 15983224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects.
    Frid AH; Nilsson M; Holst JJ; Björck IM
    Am J Clin Nutr; 2005 Jul; 82(1):69-75. PubMed ID: 16002802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion.
    Fritsche A; Stefan N; Hardt E; Häring H; Stumvoll M
    Diabetologia; 2000 Jul; 43(7):852-8. PubMed ID: 10952457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mixed Meal and Intravenous L-Arginine Tests Both Stimulate Incretin Release Across Glucose Tolerance in Man: Lack of Correlation with β Cell Function.
    Ruetten H; Gebauer M; Raymond RH; Calle RA; Cobelli C; Ghosh A; Robertson RP; Shankar SS; Staten MA; Stefanovski D; Vella A; Wright K; Fryburg DA;
    Metab Syndr Relat Disord; 2018 Oct; 16(8):406-415. PubMed ID: 30117761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.
    Nauck MA; Weber I; Bach I; Richter S; Orskov C; Holst JJ; Schmiegel W
    Diabet Med; 1998 Nov; 15(11):937-45. PubMed ID: 9827848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss.
    Škrha J; Bušek P; Uhrová J; Hrabal P; Kmochová K; Laclav M; Bunganič B; Frič P
    Pancreatology; 2017; 17(1):89-94. PubMed ID: 28027898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of the parasympathetic nervous system is necessary for normal meal-induced insulin secretion in rhesus macaques.
    D'Alessio DA; Kieffer TJ; Taborsky GJ; Havel PJ
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1253-9. PubMed ID: 11238517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
    Toft-Nielsen MB; Madsbad S; Holst JJ
    Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.
    Elahi D; McAloon-Dyke M; Fukagawa NK; Meneilly GS; Sclater AL; Minaker KL; Habener JF; Andersen DK
    Regul Pept; 1994 Apr; 51(1):63-74. PubMed ID: 8036284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients.
    Damci T; Yalin S; Balci H; Osar Z; Korugan U; Ozyazar M; Ilkova H
    Diabetes Care; 2004 May; 27(5):1077-80. PubMed ID: 15111524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia.
    Junker AE; Gluud L; Holst JJ; Knop FK; Vilsbøll T
    J Intern Med; 2016 May; 279(5):485-93. PubMed ID: 26728692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.